

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	ACCR. GOAL	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	
						REGS.	LAST	LAST	LAST	LAST	LAST	
						REGS.	Month	Month	Month	DAYS	DAYS	
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac	PREV		491	0	Y 0	Pre-Registration	649	33	17	6	4	0
							649	33	17	6	4	0
				1	Y 1	Blinded drug	124	15	4	2	1	1
				2	Y 1	Blinded drug	36	0	0	0	0	0
				3	Y 1	Blinded drug	35	0	0	0	0	0
				4	Y 1	Blinded drug	126	15	4	3	2	0
							321	30	8	5	3	1
S1007-Breast,Adj,N1, Endocrine+/-Chemo	BREAST	CCD	9400	3	Y 4	Specimen Submission for CBALR TM Substudy	65	65	65	65	24	5
							65	65	65	65	24	5
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol	SURV		817	1	Y 0	Screening	274	50	24	9	2	1
							274	50	24	9	2	1
				2	Y 1	Carvedilol	50	10	6	4	3	0
				2	Y 1	No prophylaxis	51	8	3	1	1	0
				3	Y 1	Observation	155	30	12	2	0	0
							256	48	21	7	4	0
S1600-Bladder,Radical Cystectomy Outcomes Nutrition	SXQOL		200	1	Y 1	Blinded Nutrition Drink	52	47	23	11	5	3
				2	Y 1	Blinded Nutrition Drink	57	47	28	12	6	0
							109	94	51	23	11	3
S1614-HBV in Ca Pts, TAF vs SOC	SXQOL		444	1	Y 4	SOC HBV Treatment	2	0	0	0	0	0
							2	0	0	0	0	0
S1703-Met Breast, STM-monitoring v Usual Care	CCD	SXQOL	1320	1	Y 0	Screening	285	100	49	22	9	4
							285	100	49	22	9	4
				2	Y 1	Control (Usual Care)	94	46	22	11	3	0
				2	Y 1	Intervention (STMDDM)	90	42	19	6	0	0
							184	88	41	17	3	0

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	ACCR. GOAL	O R P E E G N	ARM	TOTAL	REGS. LAST	REGS. LAST	REGS. LAST	REGS. LAST	REGS. LAST	
						REGS. REGS.	12 Month	6 Month	3 Month	30 DAYS	7 DAYS	
S1706-Breast, Inflammatory, RT +/- Olaparib	BREAST	SXQOL	300	1	Y 1	Olaparib + RT	41	9	3	1	0	0
						2 RT	49	19	9	3	1	0
							90	28	12	4	1	0
S1714-CIPN Risk Prediction Cohort Study, Taxanes	SXQOL		1050	1	Y 1	Observation	1262	795	430	192	56	13
							1262	795	430	192	56	13
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum	GU	SXQOL	1273	1	Y 0	Induction SST	450	204	97	49	15	4
						2 Y 1 Standard Systemic Therapy Only	152	65	37	20	5	1
						2 Y 1 SST + Surgery/RT	157	68	41	20	9	2
							309	133	78	40	14	3
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab	GU	SXQOL	475	1	Y 0	Initial Registration	226	120	69	34	8	2
						2 Y 1 Chemo + RT	103	55	29	14	4	2
						2 Y 1 Chemo + RT + Atezolizumab	106	59	36	18	5	1
							209	114	65	32	9	3
S1820-Rectal, Diet modification to manage GI sx	PEOLC	SXQOL	94	1	Y 0	Run-In	94	59	28	10	6	0
						2 Y 1 Diet Modification Coaching	38	25	13	6	4	1
						2 Y 1 Healthy Living Education	36	26	11	2	0	0
							74	51	24	8	4	1
S1823-GCT, Obs. Cohort, miRNA371	PREV		956	1	Y 1	Observation	305	293	166	84	25	7
							305	293	166	84	25	7
S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD	LYMPH	SXQOL	987	1	Y 1	Nivolumab + AVD	297	182	91	44	14	5
						2 Brentuximab Vedotin + AVD	294	178	90	44	14	4
							591	360	181	88	28	9

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	ACCR. GOAL	O R P E E G N ARM	REGS. LAST	REGS. LAST	REGS. LAST	REGS. LAST	REGS. LAST	REGS. LAST
S1827-SCLC, MRI Surveillance +/- PCI	LUNG	SXQOL	668	1 Y 1 PCI + MRI brain surveillance	32	26	16	6	3	1
				2 MRI brain surveillance	32	24	15	6	3	1
					64	50	31	12	6	2
S1904-Breast, Decision making for chemoprevention	PREV		415	1 Y 1 Standard Education Materials	41	41	21	11	2	1
				2 Support Tools + Standard Education Materials	38	38	33	24	9	5
					79	79	54	35	11	6
S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship	CCD		536	1 Y 2 Control	1	1	1	1	1	1
					1	1	1	1	1	1
					1	1	1	1	1	1
S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo	LUNG	SXQOL	480	1 Y 1 Atezolizumab and SBRT	29	28	19	10	2	1
				2 SBRT	29	27	18	9	3	1
					58	55	37	19	5	2
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP	LYMPH	SXQOL	422	1 Y 1 CC-486 + R-miniCHOP	4	4	4	3	1	1
				2 R-miniCHOP	5	5	5	3	1	1
					9	9	9	6	2	2
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O	LEUK	SXQOL	247	1 Y 1 Delayed V-O	4	4	4	2	0	0
				2 Early V-O	7	7	5	2	0	0
					11	11	9	4	0	0
S2013-I-CHECKIT: ICI toxicity risk prediction study	SXQOL		2062	1 Y 1 Observation Arm	5	5	5	5	2	1
					5	5	5	5	2	1
					5	5	5	5	2	1
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib	BREAST	SXQOL	1	E	5	5	4	2	0	0
					5	5	4	2	0	0
					5	5	4	2	0	0
A021502-Colon, Stg III, Chemo +/- Atezol, ATOMIC	GI	SXQOL	1	E	53	21	8	4	0	0
					53	21	8	4	0	0
					53	21	8	4	0	0

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	ACCR. GOAL	O R P E E G N ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.
					REGS.	LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS
A021806-Pancreas, Perioperative vs Adjuvant Chemo	GI	SXQOL	0	E	10	9	6	3	1	0
					10	9	6	3	1	0
					1	E	9	8	6	4
					9	8	6	4	1	0
A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	GU	SXQOL	1	E	9	2	1	0	0	0
					9	2	1	0	0	0
A031704-RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo	GU	SXQOL	1	E	68	36	9	5	1	0
					68	36	9	5	1	0
					2	E	42	29	13	4
					42	29	13	4	0	0
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO	LUNG	SXQOL	1	E	30	30	21	10	3	0
					30	30	21	10	3	0
ACCL16N1-Guideline Consistent Treatment AYA ALL	CCD		1	T	54	0	0	0	0	0
					54	0	0	0	0	0
EA2186-PANC, mets, Gem+Abraxane vs GI 5-FU+LV+Nal-IRI		SXQOL	1	E	13	13	7	4	0	0
					13	13	7	4	0	0
EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	MELAN	SXQOL	1	E	54	5	0	0	0	0
					54	5	0	0	0	0
					2	E	21	4	1	0
					21	4	1	0	0	0
EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE)	MMYEL	SXQOL	0	E	6	6	6	3	2	0
					6	6	6	3	2	0
					1	E	3	3	3	1

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	ACCR. GOAL	O R P E E G N ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.
					REGS.	LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS
					3	3	3	1	1	1
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT	BREAST	SXQOL	1	E	7	5	3	0	0	0
					7	5	3	0	0	0
			2	E	8	6	5	1	0	0
					8	6	5	1	0	0
NRGBR004-BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo	BREAST	SXQOL	1	E	9	4	2	1	0	0
					9	4	2	1	0	0
			2	E	6	3	2	1	0	0
					6	3	2	1	0	0
NRGCC003-SCLC, PCI or HA-PCI	LUNG	SXQOL	1	E	4	0	0	0	0	0
					4	0	0	0	0	0
			2	E	4	0	0	0	0	0
					4	0	0	0	0	0
NRGGU005-PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT	GU	SXQOL	1	E	7	5	1	1	1	0
					7	5	1	1	1	0
NRGLU002-LUNG, Limited Met NSCLC, MST vs LCT + MST	LUNG	SXQOL	1	E	2	1	0	0	0	0
					2	1	0	0	0	0
A021602-PANC, Adv PNET Blinded Cabozantinib v Placebo	GI	SXQOL	1	E	15	7	5	3	1	0
					15	7	5	3	1	0
A031801-GU, mRCC, Cabozantinib +/- Radium-223	GU	SXQOL	1	E	3	3	1	1	0	0
					3	3	1	1	0	0
A031902-Pros, Adv, Enzalutamide + Rucaparib	GU	SXQOL	0	E	2	2	2	2	2	1
					2	2	2	2	2	1

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	ACCR. GOAL	O R P E E G N ARM	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS
A071801-Brain, Mets, Post-Srg Single SRS vs Fract SRS	OTHER	SXQOL	0	E	1	1	1	0	0	0
					1	1	1	0	0	0
				1	1	1	0	0	0	
A191901-Brst, Text/Motivational Intervention ET Adher	CCD		1	E	17	17	17	15	5	0
					17	17	17	15	5	0
				1	17	17	17	15	5	0
A211102-Breast, Atypia via RPFNA, Metformin v Placebo	PREV		0	E	6	0	0	0	0	0
					6	0	0	0	0	0
				1	3	0	0	0	0	0
A211601-Breast, Stg II-III, Aspirin	PREV		1	E	2	0	0	0	0	0
					2	0	0	0	0	0
				1	2	0	0	0	0	0
A221702-BREAST, SLN/ALND +/- ARM	SXQOL		1	E	15	0	0	0	0	0
					15	0	0	0	0	0
				1	15	0	0	0	0	0
A221805-Colorectal, Duloxetine for Oxaliplatin CIPN	SXQOL		1	E	3	2	1	0	0	0
					3	2	1	0	0	0
				2	2	2	2	2	0	0
A231601C-CCD, OPTI-Surg in older cancer patients	CCD		1	E	1	1	0	0	0	0
					1	1	0	0	0	0
				1	1	1	0	0	0	0
A231602C-Blood Cancer, Assess Financial Difficulty	CCD		1	T	4	0	0	0	0	0
					4	0	0	0	0	0
				1	4	0	0	0	0	0

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	ACCR. GOAL	O R P E E G N ARM	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS
A231701C-Brst, Srg Decision Engagement	CCD		1	E	1	1	1	0	0	0
					1	1	1	0	0	0
AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult	ERLYTX	SXQOL	1	E	1	1	1	1	1	0
					1	1	1	1	1	0
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo	OTHER	SXQOL	1	T	1	0	0	0	0	0
					1	0	0	0	0	0
EA2185-Impact of Panc Cyst Surveillance	PREV	SXQOL	1	E	3	3	2	0	0	0
					3	3	2	0	0	0
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT	GU	SXQOL	1	E	8	2	1	1	0	0
					8	2	1	1	0	0
EAA173-MYEL, SMM, Rd +/- Daratumumab	MMYEL	SXQOL	0	E	31	13	5	3	2	0
					31	13	5	3	2	0
			1	E	14	5	1	1	1	0
					14	5	1	1	1	0
EAQ171CD-Smoke Free Support Study 2.0	CCD		0	E	1	0	0	0	0	0
					1	0	0	0	0	0
			1	E	1	0	0	0	0	0
					1	0	0	0	0	0
EAZ171-Breast, Stg I-III, TIPN Docetaxel/Paclitaxel	SXQOL		1	E	3	2	0	0	0	0
					3	2	0	0	0	0
G0263-Cerv, Stg I/IIA, adjv RT vs chemoRT	OTHER	SXQOL	1	E	1	0	0	0	0	0
					1	0	0	0	0	0

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	ACCR. GOAL	O R P E E G N ARM	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS
NHLBIMDS-LEUK, National MDS Study	CCD			1 E	136	50	24	13	4	0
					136	50	24	13	4	0
NRGBN003-Mening, Grd II, Observation vs Irradiation	OTHER	SXQOL		1 E	5	0	0	0	0	0
					5	0	0	0	0	0
					2 E	3	0	0	0	0
					3	0	0	0	0	0
NRGBN007-Brain, New Dx, Ipi + Nivo vs Temozomide	OTHER	SXQOL		1 E	3	3	3	1	1	0
					3	3	3	1	1	0
					2 E	1	1	1	1	1
					1	1	1	1	1	0
NRGCC007-CCD, Increased Dose of SCP in Pros Survivors	CCD			0 E	20	20	10	5	4	0
					20	20	10	5	4	0
					1 E	20	20	10	5	4
					20	20	10	5	4	0
NRGCC008-Ovar, BRCA1, non-inferiority of BLS vs BSO	PREV	SXQOL		1 E	1	1	0	0	0	0
					1	1	0	0	0	0
NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy	GI	SXQOL		1 T	15	1	1	1	1	0
					15	1	1	1	1	0
NRGGY005-OVAR, Cedir vs Olaparib vs C+O vs Std of Care	OTHER	SXQOL		1 E	4	0	0	0	0	0
					4	0	0	0	0	0
NRGGY009-Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev	OTHER	SXQOL		1 E	10	2	1	1	1	1
					10	2	1	1	1	1

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	ACCR. GOAL	O R P E E G N ARM	TOTAL	REGS. LAST	REGS. LAST	REGS. LAST	REGS. LAST	REGS. LAST	
					REGS.	12 Month	6 Month	3 Month	30 DAYS	7 DAYS	
NRGGY018-Endo, Stg III-IVB/Recur, Pac/Carbo +/- Pembro	OTHER	SXQOL	1	E	5	5	5	2	2	0	
					5	5	5	2	2	0	
				2	E	1	1	1	1	0	0
					1	1	1	1	0	0	
NRGGY020-Endo, Erly Stg, Rando RT +/- Pembro	OTHER	SXQOL	1	E	1	1	1	1	1	0	
					1	1	1	1	1	0	
NRGHN001-Nasopharyngeal , Individual Tx EBV	OTHER	SXQOL	1	E	9	0	0	0	0	0	
					9	0	0	0	0	0	
				2	E	8	0	0	0	0	0
					8	0	0	0	0	0	
NRGHN004-HN, Adv, RT+Durvalumab vsOTHER RT+Cetuximab	OTHER	SXQOL	1	E	6	1	0	0	0	0	
					6	1	0	0	0	0	
				2	E	6	1	0	0	0	0
					6	1	0	0	0	0	
NRGHN005-HN, early stg P16-pos, randomize de-intensifi	OTHER	SXQOL	1	E	5	2	1	1	1	1	
					5	2	1	1	1	1	
NRGHN006-HN, Erly Stg, Biopsy vs Dissection	OTHER	SXQOL	2	E	1	1	1	1	0	0	
					1	1	1	1	0	0	
NRGLU005-LUNG, LS-SCLC, ChemoRT LUNG v ChemoRT+Atezo	OTHER	SXQOL	1	E	9	8	8	2	0	0	
					9	8	8	2	0	0	
R0724-Cervical, Chem+RT +/- Adj. Chemo	OTHER	SXQOL	1	E	1	0	0	0	0	0	

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	ACCR. GOAL	O R P E E G N	ARM	TOTAL	REGS. LAST	REGS. LAST	REGS. LAST	REGS. LAST	REGS. LAST
						REGS. REGS.	12 6 3 30 7	Month	Month	Month	DAYS
						1	0	0	0	0	0
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux	OTHER	SXQOL	1	E		5	1	1	1	0	0
						5	1	1	1	0	0
			2	E		4	1	1	1	0	0
						4	1	1	1	0	0
R1308-Lung, Stg II/III, Photon vs Proton Chemo RT	LUNG	SXQOL	1	E		1	1	1	1	1	0
						1	1	1	1	1	0